BIFRF (Biofrontera AG) Moat Score: 0/10 (As of Jul. 04, 2026)


BIFRF Biofrontera AG BIFRF
58 GF Score
Price $22.68
GF Value $31.34
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Moat Score?

Biofrontera AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Biofrontera AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biofrontera AG might have No Moat - No discernible moat.

Biofrontera AG  (OTCPK:BIFRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biofrontera AG Moat Score Related Terms

BIFRF
58GF Score
Biofrontera AG BIFRF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (BIFRF) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.

Key valuation signals for BIFRF:

  • Moat Score: 0
  • GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for BIFRF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.68
Price
$31.34
GF Value